Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.70 +1.02%

+$0.02 today

Market cap
$241.11M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 10.55M

Average 10.19M

Balance Sheet

Inspect the capital base behind the business.

Assets

$415.90M

FY 2025 · Annual

-24.2% YoY

Liabilities

$123.36M

FY 2025 · Annual

-2.5% YoY

Equity

$292.54M

FY 2025 · Annual

-30.7% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents173.31M61.9M83.16M75.22M51.69M
Short-term Investments283.99M455.42M365.54M217.26M198.52M
Net Receivables001.7M1.9M1.5M
Inventory00000
Other Current Assets011.5M09.01M6.04M
Total Current Assets471.32M528.82M459.12M303.39M257.75M
Property, Plant & Equipment (Net)181.02M196.43M163.18M131.26M112.73M
Goodwill00000
Intangible Assets00000
Long-term Investments382.38M76.47M3.65M80.67M8.04M
Tax Assets00000
Other Non-current Assets16.11M19.86M16.9M33.39M37.39M
Total Non-current Assets579.51M292.76M183.72M245.32M158.16M
Total Assets1.05B821.58M642.84M548.71M415.91M
Account Payables10.26M13.89M5.9M5.39M4.27M
Short-term Debt00000
Tax Payables00000
Deferred Revenue156K95K86K00
Other Current Liabilities16.13M17.94M11.66M12.15M10.24M
Total Current Liabilities47.91M53.73M37.08M35.52M32.51M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities7.79M5.85M5.18M7.76M15.8M
Total Non-current Liabilities77.72M100.97M93.53M91.01M90.85M
Total Liabilities125.63M154.7M130.6M126.53M123.36M
Common Stock142K144K169K212K229K
Retained Earnings(894.55M)(1.23B)(1.56B)(1.82B)(2.01B)
Accumulated OCI(2.57M)(9.93M)(955K)(89K)269K
Other Stockholders Equity00000
Minority Interest00000
Total Equity925.2M666.88M512.23M422.18M292.54M
Total Debt73.13M101.12M95.12M90.76M83.25M
Net Debt(100.19M)39.22M11.97M15.54M31.57M

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$30.3M
Short-term Investments$236.6M
Receivables$1.3M
Other Current$5.1M
Total Current Assets$273.3M
PP&E (Net)$108.8M
Long-term Investments$10.3M
Other Non-current$3.5M
Total Non-current Assets$122.7M
Total Assets$396.0M

Analysis

Selected assets total $396.0M for Latest. The largest visible component is Short-term Investments at $236.6M, about 59.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 6, 2026
8-KCurrent reportNov 5, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
4Statement of changes in beneficial ownershipOct 23, 2026

How much cash does ALLO have?

Allogene Therapeutics, Inc. (ALLO) reported $51.69M in cash and equivalents in fiscal 2025.

How much debt does ALLO carry?

Allogene Therapeutics, Inc. (ALLO) reported $83.25M of total debt, with net debt of $31.57M.